Table 3.

Primary efficacy endpoint by periorbital indication. Proportion of ‘improved’ or ‘much improved’ GAIS scores for periorbital indications as assessed by both investigator and subject

Main analysis (month 3 GAIS score, n = 157)			Sensitivity analysis (GAIS score at 29-153 days post-treatment or directly post-injection, n = 244)
Indication	Sample size	‘Improved’ or ‘much improved’ (n, %)	Indication	Sample size	‘Improved’ or ‘much improved’ (n, %)
Tear trough	53	41 (77.4%)	Tear trough	89	75 (84.3%)
Palpebromalar groove	43	31 (72.1%)	Palpebromalar groove	61	47 (77.0%)
Crow’s feet	24	17 (70.8%)	Crow’s feet	38	31 (81.6%)
Outer canthus	25	18 (72.0%)	Outer canthus	37	29 (78.4%)
Brow	12	8 (66.7%)	Brow	19	15 (78.9%)